The short version of GIP receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
=== Mobility === When "Ca. M. multicellularis" is free-swimming, it travels along elongated helical or straight pathways. The consortium has a co-ordinated flagellar rotation, where the organism's body rotates about its axis at the same time and in the same direction as its trajectory. This appears to prevent the formation of a single flagellar bundle while swimming. Under free-swimming conditions, the organism displays spontaneous and temporary shifts back-and-forth along magnetic field lines, known as "ping pong movement" or "escape motility". These rapid directional changes, of nearly 180°, have been interpreted as consistent with a synchronised reversal of flagellar rotation. This movement allows the organism to move more freely under the constraints of a magnetic field.
Heart rate reduction, i.e., decrease of the resting heart rate (negative chronotropic effect) and reduction of excessive elevations resulting from exercise or stress. Reduction of the force of contraction, i.e., decrease in contractility (negative inotropic effect), which lessens how hard each heartbeat contracts. Decrease in cardiac output, i.e., decrease in both heart rate and contractility within myocardium cells, where β1 is predominantly located, overall blood output per minute lowers called cardiac output/dysfunction, allowing decreased demands placed onto impaired hearts, reducing oxygen demand-supply mismatch. Lowering of blood pressure. Antiarrhythmic effects, such as supraventricular tachycardia prevention. Metoprolol also prevents electrical wave propagation. Metoprolol inhibits CYP2J2.
24 October – Data from National Records of Scotland indicates there were 24,427 deaths in Scotland between December 2022 and March 2023, 11% higher than the previous year, and the highest number since the winter of 1989–90. Jason Grant, who was hired as Scotland's first period dignity officer in 2022 but then lost the post after it was discontinued amid controversy over the appointment of a male, has settled with his employers out of court for a case of sex discrimination. 24 October – Anas Sarwar, the leader of Scottish Labour, accuses Israel of a "clear breach" of international law in Gaza and says there is "no justification for the withholding of essential supplies" from the people of Gaza. His comments come after a number of Scottish Labour resignations by officials who disagree with Keir Starmer's stance on the conflict. 25 October – Christopher McGowan is sentenced to life imprisonment with a minimum term of 23 years for the murder of his girlfriend of eight weeks, Claire Inglis, which took place after he was bailed to her address. 26 October – The Times reports that WhatsApp messages sent by National Clinical Director Jason Leitch cannot be handed to the UK or Scottish COVID-19 inquiries because he deleted them on a daily basis. Scottish band Young Fathers win the 2023 Scottish Album of the Year Award for their fourth album, Heavy Heavy. Scottish Labour leader Anas Sarwar breaks with the stance of Labour's leader, Sir Keir Starmer, on the Israel–Hamas conflict by calling for a ceasefire in Gaza.
R2NH + R'C(O)Cl + (CH3CH2)3N → R'C(O)NR2 + [(CH3CH2)3NH]+Cl− Like other tertiary amines, it catalyzes the formation of urethane foams and epoxy resins. It is also useful in dehydrohalogenation reactions and Swern oxidations. Triethylamine is readily alkylated to give the corresponding quaternary ammonium salt:
Sources: en.wikipedia.org
Table 8 gives the material and isotopic ratio defining the δ = 0 scale for each of the indicated elements. In addition, Table 8 lists the material with the 'best' measurement as determined by Meija et al. (2016). "Material" gives chemical formula, "Type of ratio" is the isotopic ratio reported in "Isotope ratio", and "Citation" gives the article(s) reporting the isotopic abundances on which the isotope ratio is based. The isotopic ratios reflect the results from individual analyses of absolute mass fraction, reported in the cited studies, aggregated in Meija et al. (2016), and manipulated to reach the reported ratios. Error was calculated as the square root of the sum of the squares of fractional reported errors.
===== U.S. government think tanks ===== Government think tanks are also important in the United States, particularly in the security and defense field. These include the Center for Technology and National Security Policy at the National Defense University, the Center for Naval Warfare Studies at the Naval War College, and the Strategic Studies Institute at the U.S. Army War College. The government funds, wholly or in part, activities at approximately 30 Federally Funded Research and Development Centers (FFRDCs). FFRDCs, are unique independent nonprofit entities sponsored and funded by the United States government to meet specific long-term technical needs that cannot be met by any other single organization. FFRDCs typically assist government agencies with scientific research and analysis, systems development, and systems acquisition. They bring together the expertise and outlook of government, industry, and academia to solve complex technical problems. These FFRDCs include the RAND Corporation, the MITRE Corporation, the Institute for Defense Analyses, the Aerospace Corporation, the MIT Lincoln Laboratory, and other organizations supporting various departments within the United States Government. Similar to the above quasi-governmental organizations are Federal Advisory Committees. These groups, sometimes referred to as commissions, are a form of think tank dedicated to advising the US Presidents or the Executive branch of government. They typically focus on a specific issue and as such, might be considered similar to special interest groups.
To carry out its work, the search unit would collect the necessary information about missing persons, analyze the information collected, strengthen and streamline processes for identifying mortal remains in coordination with the National Institute of Legal Medicine and Forensic Sciences, guarantee families' participation, and present an official report to families informing them of the fate of missing relatives. The search unit would be administrative and financially independent and autonomous, complementing the other components of the Comprehensive System.
=== Measurement === Several techniques are used to measure hemoglobin A1c. Laboratories may use high-performance liquid chromatography, immunoassay, enzymatic assay, capillary electrophoresis, or boronate affinity chromatography. Point of care (e.g., doctor's office) devices use immunoassay boronate affinity chromatography. In the United States, HbA1c testing laboratories are certified by the National Glycohemoglobin Standardization Program to standardize them against the results of the 1993 Diabetes Control and Complications Trial (DCCT). An additional percentage scale, Mono S has previously been in use by Sweden and KO500 is in use in Japan.
Isotope-ratio mass spectrometry (IRMS) is a specialization of mass spectrometry, in which mass spectrometric methods are used to measure the relative abundance of isotopes in a given sample. This technique has two different applications in the earth and environmental sciences. The analysis of 'stable isotopes' is normally concerned with measuring isotopic variations arising from mass-dependent isotopic fractionation in natural systems. On the other hand, radiogenic isotope analysis involves measuring the abundances of decay-products of natural radioactivity, and is used in most long-lived radiometric dating methods.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.